Cristiano Ronaldo has invested $7.5 million to acquire a 10% equity stake in HBL Pro2col Software LLC, an indirect wholly-owned subsidiary of Herbalife Ltd. (NYSE: HLF) that develops the company’s Pro2col technology platform. The announcement came alongside Herbalife’s fourth-quarter 2025 earnings results on February 18, 2026, leading to a significant surge in Herbalife’s stock price.
Pro2col is Herbalife’s next-generation digital personalized health and wellness operating system, which collects users’ health and lifestyle data to generate customized nutrition and wellness plans using a data-driven approach. Ronaldo’s investment includes a commitment to provide services and sponsorship rights to the platform.
In a statement shared by Herbalife, Ronaldo described the move as a natural progression of their partnership: “natural evolution” of their partnership; “what motivates [him] at this stage of [his] career.”
Ronaldo has been a paid ambassador for Herbalife since 2013, promoting co-branded products like Herbalife24 CR7 Drive. This marks his first publicly disclosed equity investment in the company.
Herbalife’s stock rose over 15% in trading following the announcement on Thursday morning (February 19, 2026), reflecting investor optimism about the high-profile endorsement and its potential to drive engagement in personalized nutrition.
The company reported a 6.3% sales increase in Q4 2025 and modest 1% full-year growth compared to 2024, amid ongoing challenges including a long-term decline in share value over the past five years and past regulatory issues (e.g., a 2016 FTC settlement).
The investment aligns with Ronaldo’s focus on health, nutrition, and business ventures, complementing his status as the world’s highest-paid soccer player (with significant off-field earnings) and his massive global following.